News | January 07, 2010

Prostate Cancer Research Gets New Funding

January 8, 2010 - The Prostate Cancer Foundation (PCF) will fund at least 10 new Creativity and 20 new multi-year Young Investigator Awards in the first half of 2010 to support innovative research in the field of cancer research.

This new round of funding will support many projects that would otherwise be left unfunded due to cutbacks in federal funding and the global recession.

"We are delighted to announce that we will be funding more than 30 new game-changing research projects in 2010 in addition to the 48 research programs that we are already supporting," commented Jonathan W. Simons, M.D., president, CEO, and David H. Koch, chair of the Prostate Cancer Foundation.

"The commitment of our donors enables us to continue advancing cancer research at a time when other funding sources are shrinking. In 2009, PCF donors contributed more than U.S. $36.5 million-just shy of our 2008 total of $37.2 million-to support PCF's research enterprise. Gifts to the PCF ranged from $5.00 to $5 million. We are grateful to our supporters, both large and small, for making ongoing research progress against prostate cancer possible," they said in a public statement.

PCF funded 10 Creativity Awards in 2009 and 20 Young Investigators in 2008. The foundation will release its list of 2010 Young Investigators in March. The deadline for the Creativity Awards Request for Applications is January 31.

"PCF's Creativity and Young Investigator programs are designed to accelerate scientific research and discovery for funding new treatments and ultimately cures for this disease," commented Howard Soule, Ph.D., PCF's chief science officer responsible for overseeing the foundation's funded research programs. "Traditionally, 70 percent of our Creativity Award recipients go on to earn additional funding for their programs. Our Young Investigators are the human capital bringing new ideas to cancer research. They are energizing the fight against prostate as well as other cancers."

For more information: www.pcf.org

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation